We reported the dural AVF case with sinus stenosis, that was entirely treated through the stenting procedure. 61-year-old male had been realizing the attack which causes bilateral visual problem. He would have suffered from the intracranial hypertension caused by dural AVF in the right transverse sinus and left transverse sinus stenosis. We performed TVE and sinus stenting, then used the antiplatelet and the anticoagulant. However, six months later, he suffered from SAH due to recurrence of dural AVF. We performed TVE again, denser packing than usual. Two years later, he have no symptom, angiographically, there was no recurrence of dural AVF and patency of stented sinus.
Case Presentation
61-year-old male had been realizing the attack which causes bilateral visual problem. When he visited a hospital, it is pointed out that he suffered from the dural AVF in the transverse sinus and the intracranial hypertension, thus he was transferred to our hospital for the advanced treatment.
The right external carotid angiogram shows the occlusion of right sigmoid sinus and the left transverse sinus stenosis, resulting in the reflux to the contralateral transverse sinus and SSS ( figure 1A,B ).
Dural AVF elicits the impairment of the normal venous circulation. The flow in the straight sinus is anterograde, albeit a little weak, and runs into the left transverse sinus via the confluence (figure 1C,D).
First of all TVE performed through the contralateral transverse sinus yielded the disappearance of the flow to the dural AVF from the right EC. This procedure caused any amelioration other than the ICP reduction from 41 cm H 2 O to 29 cm H 2 O.
Angiography followed after the TVE still revealed the flow to the confluence from left EC and the mild proceeding of the left transverse sinus stenosis ( figure 2A ). Then, both TAE through the left EC and PTA/stenting procedure to the left transverse sinus stenosis were planned.
Introduction
As regards the stenting procedure for sinus stenosis there are only a few reports in publication 1-4 , besides both long-term patency and complication seem to be unclear.
We reported the dural AVF case with sinus stenosis that was entirely treated through the stenting procedure, though it had SAH caused by recurrence of dural AVF during the followup period. 
Post-operative Course
After the sinus stenting, we use antiplatelet and the anticoagulant. ICP was lowered all the way to 21 cm H 2 O as well as the reduction in the enlargement of Marriott blind spot and the improvement of the visual disturbance. However, six months later he had severe headache and was transferred to our hospital. CT scan shows the SAH mainly in the interhemispheric cistern ( figure 3) . Bilateral ECAG shows the brand-new A-V shunts from STA and MMA with the cortical reflux ( figure 4A,B; arrow) .
Right OA angiography revealed the dural AVF in the right transverse sinus with cortical reflux ( figure 4D: arrow) , which appeared to be extinct after the first treatment (figure 4C: arrow).
Second TVE
Microcatheter was easily inserted into the coils which was put on the last time and the coiling was started from the center of old coils with the use of mainly GDC10 coils. Denser sinus packing was performed than usual, besides the TAE was performed following the TVE. After all the procedures the dural AVF and AV shunt disappeared angiographically. Postoperative ICAG shows the improvement of the venous circulation time and brand-new anterograde venous circulation in the right transverse sigmoid sinus. Then we did not use antiplatelet and the anticoagulant.
In the angiography performed two years af-ter the treatment there isn't any finding of the dural AVF and AV shunt ( figure 5A,B ). Anterograde flow in the right transverse-sigmoid sinus appears to be developed (figure 5C: arrow) and the patency in the region of stenting in the left transverse sinus is preserved without medication (figure 5D: arrow). Discussion Table 1 shows sinus stenting for the treatment of venous hypertension. All cases used the antiplatelet or the anticoagulant after stent-ing. Since in our case the occlusion of the stent would turn out to the lethal outcome, we used the antiplatelet and the anticoagulant, Aspirin 200mg/day and Warfarin 1-2 mg/day. INR controlled under 2.5.
Angiographical circulation time and Marriot
There is a possibility that the antiplatelet and the anticoagulant prescribed after the TVE might have inhibited the thrombus formation and organization, eventually assisted the recurrence of the dural AVF.
We think the antiplatelet and the anticoagulant treatment should have not been commenced until the thrombus formation and the organization after the TVE are completed. If necessary, denser embolizations should have performed than usual, in case of dural AVF with sinus stenting.
Another question is, after the certain period, the antiplatelet and the anticoagulant treatment would not be required?
In our case, we use antiplatelet and the anticoagulant treatment to eight months after sinus stenting, but do not use after haemorrhagic complication. The patency in the region of stenting is preserved without medication for two Shin-ya Fukumoto, M.D. Department of Neurological Surgery Ehime University School of Medicine Toon city, Ehime, 791-0295, Japan E-mail: fukumoto@m.ehime-u.ac.jp Table 1 Sinus stenting for the treatment of venous hypertension.
